Core Insights - Lufthansa's financial performance for fiscal year 2025 is better than expected due to stricter financial management and fleet updates [1][2] - The adjusted operating profit is reported at €2 billion (approximately $2.32 billion), exceeding analyst expectations of €1.9 billion and surpassing the adjusted operating profit of €1.6 billion for 2024 [1][2] - The operating profit margin stands at 4.9%, an increase from 4.4% in 2024 [3] Financial Projections - Lufthansa plans to increase its operating profit margin to 8%-10% between 2028 and 2030, recovering from the 4.4% margin in 2024 [3] - The company anticipates a 4% growth in capacity for 2026, along with revenue and profit margin growth, despite geopolitical uncertainties affecting the outlook for that year [3]

Core Viewpoint - Luoyang Molybdenum Co., Ltd. is a major player in the non-ferrous metal mining industry, focusing on the production of molybdenum, tungsten, cobalt, and other metals, with significant market positions globally [3][4]. Group 1: Company Overview - The company is one of the top five molybdenum producers and the largest tungsten producer globally, as well as the second-largest cobalt and niobium producer [3][4]. - Luoyang Molybdenum is also the second-largest producer of phosphate fertilizer in Brazil, with a complete phosphate industry chain [4]. - The company has a diversified revenue stream, with refined metal product trade contributing 48.56% and copper 27.14% to its total revenue [8]. Group 2: Production and Financial Performance - In 2022, the company's gold equity production was 16,000 ounces, with a guidance of 25,000 to 27,000 ounces for 2023, representing a year-on-year increase of 56% to 69% [3]. - For the period from January to September 2025, Luoyang Molybdenum achieved a revenue of 145.485 billion yuan, a decrease of 5.99% year-on-year, while net profit attributable to shareholders increased by 72.61% to 14.280 billion yuan [9]. - The company has distributed a total of 21.562 billion yuan in dividends since its A-share listing, with 10.576 billion yuan in the last three years [9]. Group 3: Market Activity - On March 6, the company's stock fell by 2.70%, with a trading volume of 4.874 billion yuan and a turnover rate of 1.27%, resulting in a total market capitalization of 471.103 billion yuan [1]. - The stock is currently ranked 46th in terms of popularity in the A-share market [2]. - Recent market activity shows a net outflow of 788 million yuan from main funds, indicating a trend of reduced investment in the stock [5][6].

Core Viewpoint - Nvidia has ceased production of its H200 processors tailored for the Chinese market, indicating a lack of short-term sales expectations for this product in China [1][3]. Group 1: Production Changes - Nvidia has informed TSMC to reallocate production capacity away from the H200 to focus on the Vera Rubin chip [3]. - This decision reflects Nvidia's pessimism regarding the H200's sales prospects in the Chinese market [3]. Group 2: Regulatory Context - In mid-January, the U.S. government announced a relaxation of export regulations for Nvidia's H200 chips to China, which led Nvidia's CEO Jensen Huang to state that the supply chain for H200 had been restarted and that demand from Chinese customers was "very high" [3]. - Despite the U.S. government's approval for limited H200 product exports to China, Nvidia's CFO Colette Kress revealed that the company has not sold any H200 chips to Chinese firms and remains uncertain about future sales [3]. Group 3: Market Sentiment - Commentary from C114 suggested that Nvidia's ability to conduct substantial and long-term business in China is hindered by a lack of mutual trust between the U.S. and China [3]. - Bloomberg reported that ongoing tightening of advanced AI chip export controls by the U.S. has imposed multiple restrictions on the sales of the H200 in the Chinese market [3].

Core Viewpoint - Newman Health Food Holdings Limited, once praised as the "Farmer Spring of the maternal and infant industry," is currently facing a trust crisis in the capital market, with liquidity issues, a long-term decline in stock price, and turmoil among core executives [1][7]. Group 1: Liquidity and Stock Performance - Since its listing on the Hong Kong stock market in January 2025, Newman's stock performance has disappointed early investors, closing at HKD 0.590 on March 5, 2026, with a trading volume of only HKD 300,000 and a turnover rate of 0.05% [2][8]. - The stock has seen a 52-week high of HKD 0.893 and a low of HKD 0.500, significantly below its issue price, and even after a recent investment announcement, the market reaction remained tepid, indicating a "zombie stock" status [2][8]. Group 2: Auditor Resignation and Financial Reporting Delays - On March 3, 2026, Newman announced the resignation of its auditor due to a disagreement over audit fees, which has raised concerns about the company's financial disclosures [3][9]. - The resignation has led to a delay in the annual performance report, which is now expected to be published by April 30, 2026, instead of the statutory deadline of March 31, 2026 [4][10]. - The company cited multiple factors for the delay, including changes in key financial personnel and ongoing audit matters that remain unresolved [4][10]. Group 3: Business Performance and Market Position - Newman primarily sells dietary supplements targeting the maternal and infant market, with its main product being algal oil DHA. However, its revenue for the first half of 2025 was HKD 93.156 million, a significant decline of 36.23% year-on-year, and net profit plummeted by 95.30% to HKD 2.129 million [5][12]. - Analysts suggest that Newman is facing a growth ceiling due to intense competition in the maternal and infant sector and rapid changes in consumer preferences, with concerns raised about its recent investment in Crystal Technology as being "off-track" [6][12]. - The company is currently experiencing its darkest hour since its listing, with multiple crises occurring simultaneously, putting immense pressure on its future [6][12].

Core Viewpoint - BYD has launched its second-generation blade battery and fast charging technology, introducing the "Fast Charging China" strategy, which aims to build 20,000 fast charging stations nationwide by the end of the year, marking a significant advancement in electric vehicle charging convenience [1][10]. Group 1: Product Launch and Features - The second-generation blade battery offers improved fast charging capabilities, allowing for a full charge in 5 minutes at normal temperatures and only 3 additional minutes at -30 degrees Celsius [5]. - The energy density of the second-generation blade battery has increased by over 5% compared to the first generation, while also ensuring that fast charging does not negatively impact battery lifespan [5]. - The new battery comes with a warranty policy that enhances the capacity retention rate by 2.5%, maintaining a lifetime warranty on the battery cells [5]. Group 2: Charging Infrastructure - BYD plans to construct 20,000 fast charging stations across China, with 18,000 of these stations expected to be completed by the end of the year, ensuring coverage within 3 to 6 kilometers in urban areas [10][12]. - The fast charging stations will also be strategically placed along highways, with 2,000 stations planned to be built, ensuring that there is a station approximately every 100 kilometers [12]. - The new fast charging piles will have a charging power of 1500 kW, designed to overcome grid capacity limitations and provide a user-friendly charging solution [8]. Group 3: User Benefits and Experience - All owners of vehicles equipped with the second-generation blade battery will receive one year of free fast charging at the new stations, enhancing the user experience [3]. - The fast charging stations will feature a user-friendly design, allowing for easy access and "no-sense payment" through the BYD fast charging app [8]. - BYD has initiated a "Dream Station Building" plan, allowing users to propose new charging stations based on demand, ensuring that infrastructure meets user needs [12]. Group 4: Future Plans - BYD aims to expand its fast charging network internationally, with plans to establish fast charging stations overseas by the end of 2026, contributing to global electric vehicle development [13]. - The company continues to innovate in electric vehicle technology, showcasing new models equipped with the second-generation blade battery and fast charging capabilities, including the Tengshi Z9GT and other models [15][16].

Core Insights - Roche Pharmaceuticals China announced the approval of its antiviral treatment, Xofluza® (generic name: baloxavir marboxil), by the National Medical Products Administration of China on March 3, 2026, for treating uncomplicated influenza A and B in children aged 1 to under 5 years, including both previously healthy patients and those at high risk for influenza complications [1] Group 1: Product Approvals - On February 13, 2026, Xofluza® tablets were approved for use in adults and children aged 5 and above for uncomplicated influenza A and B, expanding the treatment age range from previously 5 years and older to 1 year and older, thus providing comprehensive coverage for infants, children, and adults [2] - The approval of these new indications is based on results from two studies conducted in children aged 1 to under 12 years, demonstrating the drug's efficacy and safety [2] Group 2: Clinical Research Findings - The MINISTONE-2 study, a global Phase III, randomized, double-blind clinical trial, showed that baloxavir marboxil had good tolerability and efficacy in children aged 1 to 12 years, significantly reducing the time to viral clearance by more than two days compared to the neuraminidase inhibitor oseltamivir (24.2 hours vs. 75.8 hours) with a lower incidence of adverse events [2] - The DRAGONSTONE study, conducted in Chinese patients aged 1 to under 12 years, compared baloxavir marboxil with oseltamivir, showing similar rates of adverse events and no new safety signals [3] Group 3: Influenza Impact - According to the World Health Organization, seasonal influenza can lead to 3 to 5 million cases of severe illness and 290,000 to 650,000 respiratory disease-related deaths globally each year, with children being particularly susceptible, having an infection rate of approximately 20% to 30%, which can rise to about 50% during peak seasons [3]

Core Viewpoint - Goldman Sachs reported that JD Logistics achieved a revenue of 63.5 billion yuan in Q4 last year, representing a year-on-year growth of 22%, slightly exceeding the bank's forecast of 21% [1] Group 1: Financial Performance - The internal comprehensive supply chain revenue reached 26.7 billion yuan, with a year-on-year growth of 68%, outperforming the bank's expectation of 10% [1] - Adjusted net profit was 2.4 billion yuan, surpassing the bank's forecast by 5% [1] Group 2: Investment Rating - Goldman Sachs has assigned a "Buy" rating to JD Logistics, with a 12-month target price of 17.4 HKD based on a sum-of-the-parts valuation method [1] - The positive outlook is supported by JD Logistics' leading position in the Chinese supply chain industry, proven business model, and technological expertise [1]

Core Viewpoint - The Hong Kong stock market has experienced a strong rebound, particularly in the internet sector, with major companies like Alibaba, Xiaomi, Meituan, and Tencent all seeing gains of over 3% [1][8]. Market Performance - The Hong Kong internet sector's current price-to-earnings ratio (PE) is 20.74, which is significantly lower than the NASDAQ 100's 32.85 and the ChiNext Index's 41.52, indicating a strong valuation margin [3][10]. - The Hong Kong internet ETF (513770) has risen by 2.49%, recovering above the 5-day moving average [1][8]. Financial Results - Recent earnings reports from internet companies have alleviated concerns about increasing losses, confirming the positive impact of AI as a "second growth curve" [3][10]. - Bilibili is projected to achieve its first annual profit in 2025, with an adjusted net profit of 2.59 billion yuan, while JD Health expects revenue and net profit growth of 26.3% and 29.16% respectively in 2025 [3][10]. Investment Outlook - Analysts suggest that the technology sector remains a long-term investment focus for Hong Kong stocks, with the recent market correction creating buying opportunities [3][10]. - The rise of AI capabilities in China is expected to bolster market confidence, with attention on the progress of large model applications and overseas liquidity trends [3][10]. ETF and Fund Information - The Hong Kong internet ETF (513770) and its linked funds (Class A 017125; Class C 017126) passively track the CSI Hong Kong Internet Index, with top holdings including Alibaba, Tencent, Xiaomi, Kuaishou, and Bilibili, collectively accounting for over 76% of the fund [3][11]. - For investors looking to reduce volatility, the Hong Kong Large Cap 30 ETF (520560) offers a "technology + dividend" strategy, featuring both high-growth tech stocks and stable dividend-paying companies [5][11].

Group 1 - The Hang Seng Index opened up by 0.15% [1] - The Hang Seng Tech Index increased by 0.47% [1] - JD Logistics rose by over 6% [1] - JD Health and Trip.com Group both increased by over 3% [1] - NetEase, JD Group, and Xiaomi Group showed significant gains [1]

Core Viewpoint - Li Auto is set to launch a dual-wheeled robot within this year, primarily for factory manufacturing scenarios, indicating the company's expansion into robotics technology [1] Group 1: Company Developments - Li Auto's stock price increased by 2.97%, reaching HKD 67.55, with a trading volume of HKD 238 million [1] - The humanoid robot team at Li Auto has been in existence since April 2025 and has been secretly developing for nearly a year [1] - The internal project, codenamed Nexus, is led by He Junpei, a hardware partner from the former robotics startup Jiuguang Intelligent, with a team of fewer than 30 people [1] Group 2: Product Information - Li Auto plans to develop two products under the humanoid robot team: a dual-wheeled robot and a bipedal robot [1] - The dual-wheeled robot is reportedly ready for launch and is expected to be released by mid-year [1]